New triple therapy offers hope for elderly lung cancer patients
NCT ID NCT05685550
First seen Jan 05, 2026 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This study tests a combination of three drugs (oral etoposide, anlotinib, and envafolimab) as a first treatment for elderly patients with extensive small cell lung cancer. The goal is to see if this approach can delay cancer growth and improve survival. Thirty participants will receive up to 6 cycles of the combination, followed by maintenance therapy with two of the drugs until the disease worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSION-FREE SURVIVAL, PFS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, 300450, China
Conditions
Explore the condition pages connected to this study.